Kathleen Greenough, 4G Clinical's Senior Director of Client Solutions, recently published a guest article for International Clinical Trials, "The Need for Adaptive Trial Design in Oncology Studies." The piece dives deep into why adaptive, flexible trial design is key to the future of oncology studies.
Here's a short excerpt from the article:
Trial research needs to account for increased complexity and competition when recruiting patients in cancer studies. Patients and oncologists have more choices than ever for the placement of qualified study participants. Not only are treatments more specialized, but we are finally beginning to see positive results from decades of research.
No longer do researchers have to rely solely on traditional approaches to existing cancer treatments, such as chemotherapy. Now, patients are being considered for immunotherapy and cell and gene therapy. According to the Alliance for Regenerative Medicine, at the outset of 2021 there were 1,220 active worldwide clinical trials in regenerative medicine and advanced cell and gene therapies, with a majority (554) of them aimed at oncology.